Drug intelligence / Profile preview

autologous amniotic fluid

Development stage: Phase 4
Lead developer: Kasr Al Ainy Hospital
Administration: Local Injection

Overview

Autologous amniotic fluid is a biological product derived from a patient's own amniotic fluid, typically aspirated during a cesarean section. It is being investigated for its potential to promote wound healing, specifically in the context of cesarean section scars. The fluid contains various growth factors, cytokines, and stem cells that are believed to contribute to tissue regeneration and repair. The proposed mechanism involves injecting the fluid into the wound edges to enhance the natural healing process, reduce infection rates, and improve scar quality.

Beyond the preview

Go deeper on autologous amniotic fluid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous amniotic fluid.

Explore the full profile